Jubilant Ingrevia Ltd

- Jubilant Ingrevia plans incremental CAPEX of Rs. 600 to 800 crore per annum over the next three years, mainly focused on Specialty and Nutrition segments. - The company intends to fund most of this CAPEX through internal accruals and EBITDA generated from existing operations. - Current debt levels stand around Rs. 650-700 crore, with no plans to exceed Rs. 900-1,000 crore. - Debt coverage ratio is internally targeted to remain under 1.4x. - If needed, marginal increase in debt may be considered but no significant new debt or equity fundraising is planned at this stage.

- Wave-I CAPEX of Rs. 2,000 crore mostly completed with investments in Specialty and Nutrition segments. - Upcoming Wave-II CAPEX planned at Rs. 2,000 to 2,500 crore over the next 3 years (~Rs. 700-800 crore annually). - 100% of Wave-II investment to focus on Specialty and Nutrition portfolios. - CAPEX geared towards CDMO opportunities in agro, pharma, semiconductors; multipurpose plants for pyridine and diketene derivatives. - Additional investments in expansion and modification of agro intermediate and active plants (~Rs. 300 crore) for $300 million CDMO contract. - Strategy-led incremental CAPEX expected to be largely funded by internal accruals; aim to keep debt below Rs. 900-1,000 crore with coverage ratio under 1.4x. - New projects, including food and cosmetic grade Niacinamide plant, slated for commissioning in Q3 FY'25; more multipurpose plants planned. - Continuous focus on agile, customized facilities to meet customer demand quickly.

- Jubilant Ingrevia targets a 3x revenue increase and 4x EBITDA growth by FY'29 from the FY'24 base (Rs. 4,200 crore revenue). - Specialty Chemicals and Nutrition segments are expected to form over 75% of revenue with continued volume growth. - Specialty Chemical revenues grew 13% YoY with volume growth around 25%. - Nutrition business revenue increased 12% YoY driven by higher sales volumes (animal and human-grade Niacinamide) and rising prices. - Agrochemical demand is recovering with volumes increasing after destocking; pricing shows pockets of improvement. - The company anticipates incremental CAPEX of Rs. 600-800 crore annually for the next 3 years to support growth, mostly funded via internal accruals. - CDMO contracts (including a $300 million, 5-year agrochemical contract) signal significant volume ramp-up from FY'26 onwards. - Continued focus on high-margin Specialty and Nutrition products implies improving revenue mix and margin expansion.

- Jubilant Ingrevia targets 3x revenue and 4x EBITDA growth by FY'29 from FY'24 base (Rs. 4,200 crore revenue in FY'24). - Specialty Chemicals and Nutrition segments are expected to constitute over 75% of revenue, up from 60% currently. - EBITDA margin thresholds for new contracts are set at a minimum of 20%. - Incremental CAPEX of Rs. 600-800 crore expected annually for next three years to drive growth, primarily funded through internal accruals. - CDMO business, including two major contracts (one $300 million, five-year duration), is a key growth driver. - Continuous volume growth: Specialty Chemical volumes have grown ~25% YoY despite price pressures. - Nutrition segment (Niacinamide) shows steady volume increases and price improvement. - Cost-saving initiatives yielded Rs. 120 crore annual savings. - Net debt managed prudently around Rs. 650-700 crore, with a cap not to exceed Rs. 900-1,000 crore ensuring healthy coverage ratios.

- Jubilant Ingrevia has created a strong pipeline with over 100 opportunities from 120+ customer meetings. - They have secured two key CDMO contracts, including a $300+ million contract over five years. - The $300 million contract involves preparing their Agrochemical plant with expected production starting late calendar year 2025. - Another smaller order involves a new AI (Active Ingredient) not yet commercialized, expected to start supplying early next financial year with volumes in hundreds of tons. - The order book reflects both existing and prospective contracts in Pharma, Agrochemicals, Specialty Chemicals, and Nutrition segments. - The pipeline is expected to grow as the "China plus one" strategy and Bio Security Act drive increased outsourcing to India. - Jubilant expects their CDMO business contracts to be just the tip of the iceberg, anticipating conversion of multiple pipeline opportunities in coming years.